Brenton Mar

Leading a clinical development organization of ~20 direct and indirect reports, including physicians, clinical science, medical writing, translational medicine, clinical pharmacology, pharmacovigilance and toxicology. Driving clinical development strategy for multiple assets on Senior Leadership Team, including - Zovegalisib (RLY-2608), a first-in-class allosteric pan-mutant selective PI3Ka inhibitor with Breakthrough Designation in PIK3CA mutated HR+ HER2- breast cancer which is also being studied in rare, pediatric, non-malignant disease with PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA driven vascular malformations - Lirafugratinib, a first-in-class isoform selective FGFR2 inhibitor, authoring a successful BTD application for FGFR2-altered cholangiocarcinoma (now partnered with Elevar Therapeutics and NDA under review) - Early assets pre-IND, including a first-in-class selective NRAS inhibitor for NRAS mutated melanoma and other solids tumors and a non-inhibitory chaperone of aGal for Fabry’s disease Operational leadership, including budget ownership, CRO governance and Protocol Review Committee Serving as clinical subject matter expert during investor meetings and strategic partnerships

- Clinical lead for avapritinib, a selective KIT inhibitor for Systemic Mastocytosis, including the BTD and FDA approval for advanced SM - Drove redesign and dose selection for randomized double blind placebo controlled study with novel PRO endpoint, which resulted in global approval of avapritinib for indolent SM - Clinical lead for Lung Cancer Therapy Area, including early global development strategy for 4 investigational EGFR inhibitors (including Japan and China) and pralsetinib, a FDA/EMA approved selective RET inhibitor with BTD in RET altered NSCLC and MTC. - Member of Blueprint Medicines' governance including: Portfolio Management Team, Clinical Development Forum and the Business Development Core Team

Attended on pediatric hematological malignancies inpatient and outpatient consult services, caring for children with leukemia and lymphoma. Led precision medicine efforts to introduce real-time genomic testing into clinical trials and standard of care for leukemia patients.

Worked in the laboratory of Benjamin Ebert at Brigham and Women's Hospital on the clinical relevance of the clonal evolution of genomic mutations in acute lymphoid leukemia and collaborated with colleagues on projects in acute myeloid leukemia, myelodysplastic syndrome and clonal hematopoiesis of indeterminant potential (CHIP).

Post-doctoral work in the laboratory of Scott Armstrong, focusing on the genetics and clonal evolution of relapsed pediatric acute lymphoblastic leukemia, identifying an enrichment in mutations in epigenetic regulators at relapse.